Advancing Peptide Therapeutics — From Discovery to Development
Sri Laya Chemicals supports peptide research and development through specialized synthesis, scientific problem-solving, and analytical support for pharmaceutical and biotechnology partners worldwide.
High-affinity macrocycles, GLP-1 analogues, and constrained peptide sequences optimized for target engagement.
A Focused Approach to Peptide Science
Peptide-based drugs represent one of the most promising and rapidly expanding frontiers of modern therapeutic development. Sri Laya Chemicals is established as a dedicated partner focused on addressing the unique synthetic, structural, and analytical challenges of peptide science.
Peptide Chemistry
SPPS, solution-phase & complex ligation
Analytical Characterization
UPLC-MS, MS-MS, AAA & purity profiling
Process Development
Route scouting, resin & yield optimization
Research Support
Stability testing & reference impurities
The Science Behind the Next Generation of Therapeutics
Peptides occupy a privileged space in modern drug discovery — combining the target selectivity and potency of biologics with the synthetic precision and tissue penetration of small molecules.
Why Peptide Therapeutics Are Gaining Momentum
Historically, drug developers were constrained between small molecules that struggle to bind large, flat protein interfaces and large biologics that cannot penetrate cell membranes or be readily modified synthetically. Peptides solve this dichotomy by engaging wide, shallow binding surfaces with picomolar or nanomolar affinity.
With more than 100 peptide therapeutics approved globally and hundreds more advancing through clinical pipelines, the field is propelled by breakthrough innovations in synthesis chemistry, backbone stabilization, and metabolic half-life extension.
Targeting Protein-Protein Interactions (PPIs)
Peptides mimic natural secondary structural elements (such as α-helices and β-turns) to modulate challenging intracellular signaling cascades and oncogenic protein interfaces that small molecule drugs cannot disrupt.
Target Selectivity
Engineered sequences bind target receptors with exquisite specificity, reducing off-target interactions and minimizing adverse metabolite toxicity.
Synthetic Flexibility
Advanced solid-phase peptide synthesis (SPPS) permits rapid incorporation of non-canonical amino acids, chelators, and bioconjugates in parallel.
Metabolic Stability
Backbone modifications, D-amino acid substitution, hydrocarbon stapling, and cyclization shield against serum proteases and dramatically extend half-life.
Favorable Biodistribution
Peptides biodegrade naturally into standard amino acid building blocks, eliminating the organ-accumulation risks typical of synthetic xenobiotics.
GLP-1 and Incretin Analogues — Redefining Metabolic Medicine
The clinical and commercial validation of GLP-1 receptor agonists (such as semaglutide) and dual GIP/GLP-1 receptor co-agonists (such as tirzepatide) has transformed the treatment landscape for type 2 diabetes and obesity, demonstrating unprecedented therapeutic efficacy.
This validation has ignited intense research into next-generation incretin mimetics, requiring specialized synthetic expertise to construct complex multi-functional peptide analogues.
Active Research Frontiers (Investigational):
- Triple Agonists: Rational design of unimolecular peptides activating GLP-1, GIP, and glucagon receptors simultaneously.
- Amylin & Calcitonin Conjugates: Co-administered or covalently tethered analogues to amplify satiety signaling.
- Fatty Acid Acylation & Half-Life Extension: Albumin-binding diacid linkers engineered for monthly or extended dosing regimens.
- Beyond Metabolic Disease: Translational research assessing incretins in neurodegeneration (Alzheimer’s, Parkinson’s), cardiovascular protection, and MASH.
Overcoming Long-Sequence Synthesis Hurdles
Incretin analogues often comprise 30–40 amino acids, requiring specialized pseudoproline dipeptides, optimized resin substitution, orthogonal protecting groups for Lys-acylation, and high-efficiency purification.
Macrocyclic Peptides — The Next Frontier in Drug Design
While linear peptides are vulnerable to circulating exopeptidases and adopt multiple flexible conformational states, macrocyclization fixes the peptide backbone into a stable, bioactive architecture. This conformational pre-organization yields orders-of-magnitude improvements in binding affinity and metabolic stability.
Proteolytic Shielding
Enzymatic cleavage sites are structurally obscured, extending plasma half-lives from minutes to hours.
Chameleon Permeability
Internal hydrogen bonding enables macrocycles to shield polar groups when crossing lipophilic cell membranes.
Diverse Ring Architectures
Head-to-tail, lactam bridge, hydrocarbon staple, thioether, and bicyclic scaffold cyclization options.
Intracellular Targets
Accessing difficult undruggable pockets inside cells that conventional biologics cannot reach.
Connecting Computational Discovery with Experimental Science
Our vision unites in silico molecular intelligence with wet-lab experimental selection — establishing a closed-loop discovery framework that aims to accelerate hit-to-lead timelines for biopharma collaborators.
AI Library Design
Computational analysis of the target binding site. Machine learning models predict candidate sequences, enriching the focused library prior to wet-lab synthesis.
Phage Display Panning
Enriched peptide library displayed on phage coat proteins. Panning against target proteins isolates binders while washing away non-binding sequences.
Hit Identification
High-throughput next-generation sequencing (NGS) followed by ELISA and SPR biophysical binding verification to confirm authentic target engagement.
Lead Optimization
Comprehensive SAR, alanine scanning, backbone cyclization, and stapling to optimize potency, selectivity, and metabolic stability for pre-clinical progression.
How the Closed-Loop Discovery Cycle Operates
Every confirmed binder — along with sequence patterns and binding affinities — will be fed back into the computational model. Crucially, non-binding sequences provide negative training data, enabling the predictive algorithms to eliminate false positives in subsequent iterations.
Precision Synthesis for Complex Peptide Research
From milligram exploratory sequences to high-diversity 48-channel parallel libraries and multi-gram pre-clinical candidates, Sri Laya Chemicals delivers peptides engineered for chemical integrity and biological potency.
Custom Peptides of Any Complexity & Scale
Every custom synthesis project is executed under meticulous chemistry control — pairing optimized protecting group strategies, specialized coupling reagents, and rigorous analytical quality control.
Fmoc SPPS (Solid Phase)
High-efficiency assembly for linear, branched, and cyclic sequences up to 60+ residues.
Solution-Phase Synthesis
Convergent segment condensation for complex architectures and larger batch sizes.
Hybrid Solid/Solution
Combines rapid SPPS fragment production with scalable liquid-phase coupling.
Chemical Protein Synthesis
Native Chemical Ligation (NCL) for non-recombinant synthetic proteins and isotopic variants.
Scale Capabilities
- Milligram (mg)Early feasibility screening, binding assays, and hit confirmation.
- Gram (g)In vitro / in vivo proof of concept, PK/PD profiling, and lead optimization.
- Multi-Gram (kg scale path)Toxicology batches, formulation screening, and IND-enabling studies.
From Research Material to Development-Ready Evidence
Moving a peptide candidate toward pre-clinical evaluation demands comprehensive analytical characterization, impurity control, and scalable process understanding. Sri Laya Chemicals provides non-GMP analytical support to de-risk your development pipeline.
Peptide Impurity Synthesis
Authenticated reference standards for synthesis deletion sequences, diastereomers, and degradation variants at defined purity specifications.
Process Research & Development
Engineering scalable synthetic routes, evaluating resins and cleavage reagents, and designing robust preparative HPLC purification workflows.
Analytical Method Development
High-resolution UPLC-UV, mass spectrometry (HR-MS), MS-MS sequence verification, amino acid analysis (AAA), and residual counter-ion profiling.
Pre-Clinical Support
Early-stage stability assessments under forced degradation conditions, solubility profiling, and evidence packages for go/no-go decisions.
Structured Evidence for Reliable Translational Decisions
Synthesized accurately, analyzed rigorously, and prepared with complete analytical traceability.
Built Around Scientific Rigor and Long-Term Progress
Partnering with Sri Laya Chemicals means collaborating with a dedicated team grounded in chemical precision, dependable execution, and a clear vision for the future of peptide therapeutics.
Scientific Rigor
Every chemistry protocol is grounded in empirical data, optimized for reproducible purity and robust characterization.
Synthetic Breadth
From standard Fmoc SPPS to complex macrocycles and native chemical ligation (NCL), spanning modern peptide modalities.
Parallel Library Speed
Automated 48-channel Syro II parallel synthesis enabling rapid multi-sequence generation for accelerated SAR cycles.
Operational Reliability
Transparent communication, dependable milestone tracking, and strict adherence to agreed project deliverables.
Program Adaptability
Flexible chemistry solutions designed to pivot seamlessly as biological assays and lead optimization priorities evolve.
Long-Term Vision
A dedicated growth trajectory progressing from research-scale synthesis toward comprehensive translational capabilities.
Our Progressive Capability Roadmap
A disciplined, phased journey distinguishing current verified synthesis services from our forward-looking expansion goals.
Synthesis & Library Core
Consolidating advanced custom peptide synthesis, 48-channel parallel libraries, and structural modification workflows.
Computational Discovery
Developing an integrated computational AI library design framework alongside phage display biopanning capabilities.
Process R&D & Scale
Expanding multi-gram route optimization, impurity synthesis, and non-GMP pre-clinical analytical profiling.
GMP Infrastructure
Working toward establishing cGMP-compliant manufacturing suites to support clinical phase-1 material requirements.
Full CDMO Services
Exploring full-service CDMO operations and commercial-scale manufacturing partnerships for approved peptide therapeutics.
Let's Discuss Your Peptide Research Program
Looking for a peptide synthesis or development partner? Tell us about your research objectives and requirements, and our team can discuss the appropriate next steps.
H.No. 7-181, Plot No. 72/TA, Flat No. 301, 3rd Floor,
New Prashanthi Golden Hills, Pragathi Nagar,
Hyderabad, Medchal Malkajgiri, Telangana – 500090